Sonrgy's SonRx platform is based on nanocarriers much smaller than human cells. These carriers are designed to bring chemotherapy agents through a patient's circulation system to the tumor. A physician will then focus ultrasound energy onto the tumor to release the chemotherapy, maximizing the treatment's effect in that region.
The SonRx platform is applicable in many disease indications where local delivery is important. This patent pending technology was developed at UC San Diego and exclusively licensed by Sonrgy. The company is developing the SonRx to be compatible with established focused ultrasound systems. Learn more about this exciting field, Focused Ultrasound.